Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Tianyin Pharma Approved to Launch Diabetes Treatment

publication date: May 13, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Tianyin Pharma announced SFDA approval for a diabetes drug, Gliclazide Tablets (80 mg formulation). Gliclazide is an oral treatment for type 2 diabetes, administered when diet and exercise are not enough to control blood glucose. Patients take one or two tablets before eating to increase the production of insulin. Tinayin Pharma hopes to launch Gliclazide in July. The company did not issue any revenue projections for its newest product. More details....

Stock Symbol: (AMEX: TPI)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners